Slide relazioni 12° International Meeting Atrial Fibrillation 2017 – Atrial Fibrillation and Heart Failure: the ugly and the nasty

Mar 29, 2017 Cardiotool Uncategorized Commenti disabilitati su Slide relazioni 12° International Meeting Atrial Fibrillation 2017 – Atrial Fibrillation and Heart Failure: the ugly and the nasty

---

                                    

• Atrial fibrillation: fixed and still changeable opinions

Alessandro Capucci MD FACC,FESC,FHRS
Director, Cardiology and Arrhythmology Division
Università Politecnica delle Marche
Ancona,Italy

 

• How to follow up the patients after ablation

Leonardo Calo’
Dept. Cardiology  Policlinico Casilino -Roma

 

• Stroke Prevention in AF – Obstacles and Challenges

Gerald V. Naccarelli M.D.

 

• Genetics of Atrial Fibrillation: does it help in treatment decisions?

A. Wilde

• History of Anticoagulation – From the Beginning to Direct Oral Anticoagulants

B-Luderitz

• Is EF still the best parameter to evaluate?

Federico Guerra, MD, FESC
Cardiology and Arrhythmology Clinic
University Hospital “Ospedali Riuniti”
Marche Polytechnic University

 

• How to better evaluate the QT in cardioncology

Federico Lombardi, MD, FESC
UOC Malattie Cardiovascolari
Fondazione IRCCS Ospedale Maggiore Policlinico
Università degli Studi di Milano

 

• Cardiac rhythm detailed monitoring by an implanted pacemaker: The iECG solution

Francesco Zanon, MD, FESC, FHRS

Arrhythmia and Electrophysiology Unit, Cardiology Dept.
Santa Maria della Misericordia General Hospital
Rovigo – Italy

• New Anti Leukemic treatments deserve a Cardioncology approach

Guido Gini AOU «Ospedali Riuniti»

Università Politecnica delle Marche – Ancona

• The role of Telemedicine in implantable device for Heart Failure and its therapeutic impact: Lesson from IN-TIME Study

Dr Gabriele Zanotto

“Mater Salutis” Hospital, Legnago, Italy

 

• Atrial Fibrillation and Fibrosis: Still a strict link?

Johannes Brachmann

 

• Atrial Fibrillation: how hypo-coagulate and when The Impact of LV diastolic function in AF ablation cases – Lessons from KPAF registry

Kazuaki KAITANI

 

• Atrial Fibrillation: How to Hypocoagulate and When NOACs in Cardioversion and Ablation

Riccardo Cappato, MD
Electrophysiology & Arrhythmia Center
Humanitas Gavazzeni Clinics, Bergamo
Humanitas Research Institute, Rozzano, Milan – Italy

• Atrial fibrillation and cancer: How to organize the optimal follow up or  “The oncologist’s perspective”

Stefano Cascinu
Modena Cancer Center
Università degli Studi di Modena e Reggio Emilia- Policlinico di Modena, Italy

• Antiarrhythmic drugs? 

Christian Torp-Pedersen
Aalborg University Hospital – Denmark

 

• APIXABAN : FROM THE CLINICAL TRIALS  TO THE REAL LIFE EXPERIENCES

Giuseppe Di Pasquale, MD, FESC, FACC
Director Department of Medicine
Director Division of Cardiology
Maggiore Hospital, Bologna, Italy

• Antiarrhythmic drugs in AF Still a challenge When And How To Apply  Rate Control Therapy

Gianluca Botto MD, FESC, FEHRA

Electrophysiology Unit
Sant’ Anna Hospital
Como, Italy

• Role of class 1C AAD revisited

Juan Tamargo
Department of Pharmacology, School of Medicine Universidad Complutense, Madrid, Spain

 

• ANTIARRHYTHMIC DRUGS IN ATRIAL FIBRILLATION: STILL A CHALLENGE ROLE OF CLASS III ANTIARRHYTHMIC DRUGS REVISITED

J.Y. LE HEUZEY
Georges Pompidou Hospital
René Descartes University, Paris

• State of art in anticoagulation in non valvular Atrial Fibrillation: the additional value of Rivaroxaban real life data

Massimo Grimaldi
Ospedale “F. Miulli” – Acquaviva delle Fonti – Bari

 

• NAO or NEVER DABIGATRAN A LARGE EXPERIENCE ON THE FIELD

Pasquale Perrone Filardi
Federico II University of Naples
ITALY

 

• Does Edoxaban add anything new?

Raffaele De Caterina

G. D’Annunzio “University – Chieti and “G. Monasterio” Foundation – Pisa, Italy

 

• Atrial Fibrillation and Related Procedures Rotors are (“or not”) the clue

Claudio Tondo, MD, PhD
Cardiac Arrhythmia Research Centre  Monzino Cardiac Center, IRCCS
Dept. of Cardiovascular Sciences and Community University of Milan, Italy
Texas Cardiac Arrhythmia Institute, Austin,Tx, USA

 

• LAA occlusion: how and when

Gian Paolo Ussia 
Università degli Studi di Roma “Tor Vergata”

 

• AF in Athletes –  Characterizing Atrial Fibrillation by Translating its Causes into Health Modifiers in the Elderly

L. Mont

 

• High quality signal in arrhythmic substrate

Paolo Della Bella-  Caterina Bisceglia – Manuela Cireddu
San Raffaele Hospital Milan

 

• Subclinical atrial fibrillation: the next five years

 

R. De Ponti
Department of Heart and Vessels
Ospedale di Circolo e Fondazione Macchi University of Insubria,Varese, Italy

 

• A Cryo Anatomical Procedure to Everyone? 

Saverio Iacopino, FACC, FESC

 

• Paroxysmal and Persistent AF: Are there clinical differences?

Prof. Samuel Lévy
Aix-Marseille Université, France

 

• Atrial Cardiomyopathy, a new concept. How does it help?

Stanley Nattel, MDMontreal Heart Institute

 

 

 

 

---

---

---